It has been a rather lukewarm earnings season for the drug and biotech sector. Majority of large drug/biotech companies reported mixed results and issued fresh guidance for 2024, which was largely optimistic. Several smaller biotechs are scheduled to report earnings results this month. Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech as well as medical device companies. Per the Earnings Trends report, as of Feb 14, 80.0% of the ...